Home
The Office of Licensing & Ventures (OLV) is responsible for patents, technology licenses and new venture development for Duke University and Medical Center. Through direct, daily interaction with faculty, small and large businesses, and venture investors, we build strong relationships and strong agreements to translate academic discoveries into commercial products that benefit society, impact public health, and improve the quality of life.
Featured Technologies
Development of novel antibodies to cartilage oligomeric protein for biological investigations
Novel treatment for Nicotine Cessation
Genes involved in the pathogenesis of anxiety disorders including obsessive-compulsive disorder
P&G Hair Loss Drug Development Project
Active staining for in vivo MR imaging in the brain
Dopamine Transporter Knockout Mouse
Latest News
Leading Protein Engineering Executive Joins
April 15, 2008
Genes May Help Some Quit Smoking
April 2, 2008
Certain DNA is linked to better results, study finds
Trevena, Inc. Announces $24 Million Series A Financing
March 5, 2008
Drug Discovery Company to Focus on G-Protein Coupled Receptors
Celsion to Proceed with Phase II Pivotal Breast Cancer Trial after Receiving Supportive FDA Response
January 15, 2008
Expects to Initiate Trial in Ten US Centers
Banked Blood Loses Ability to Deliver Oxygen to Tissues
October 8, 2007
Genetic Variant Linked to Odor Perception
September 16, 2007
Separating the Brain's 'Bad' from 'Good' Iron
August 23, 2007
Duke chemists have found a way, by using 'pro-chelators' wrapped in chemical 'cages'
Mice Provide Important Clues to Obsessive-Compulsive Disorder
August 22, 2007
Sentillion's Growth Continues With Strong Q2; Signs 9 New Customers; Sells 94,130 Licenses
July 12, 2007
New HIV Test May Predict Drug Resistance
January 7, 2007
DURHAM, N.C. -- Researchers at Duke University Medical Center have developed a highly sensitive test for identifying which drug-resistant strains of HIV are harbored in a patient's bloodstream.